louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT04247035: Τreatment Standards and Outcomes of Patients With ER/PR Positive, HER2-negative Metastatic Breast Cancer
Official title: Non-Interventional, Multi-center Registry of Recording of Treatment Standards and Outcomes of Patients With ER/PR Positive, HER2-negative Metastatic Breast Cancer
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Metastatic Breast Cancer
Lead sponsor: Hellenic Society of Medical Oncology
Sponsor class: OTHER
First posted: 2020-01-29
Enrollment: 300
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Women with histological confirmed ER/PR positive, HER2-negative MBC

Brief summary: • To capture the treatment patterns and clinical characteristics of patients with ER/PR positive, HER2-negative MBC in Greece

Detailed description: * To capture the treatment patterns and clinical characteristics of patients with ER/PR positive, HER2-negative MBC in Greece
* To evaluate the outcome of patients per treatment line (objective response, progression free survival, time to disease progression per line of therapy), overall survival
* To record adverse events per line of therapy
* To recording of the causes of treatment discontinuation per line of therapy

Eligibility criteria: Inclusion Criteria:

* Women with histological confirmed ER/PR positive, HER2-negative MBC
* Age \>18 years old
* Patients initiating first or second line therapy for ER/PR positive, HER2-negative MBC
* Adequate hematologic, renal and hepatic function
* Signed informed consent (ICF)

Exclusion Criteria:

* Active malignancy other than MBC
* Active infection

Primary outcomes:
measure: Evaluation of the outcome per treatment line
timeFrame: 5 years
Secondary outcomes:
Other outcomes:
Locations:
city: Athens
country: Greece
facility: Hellenic Society of Medical Oncology
Study officials:
affiliation: HeSMO
name: Ioannis Boukovinas, Dr /Phd
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03634735: Thiamin Against Robust IBD Fatigue
Official title: Thiamin Against Robust IBD Fatigue
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Fatigue
Keywords: Inflammatory Bowel Disease
Fatigue
Thiamine
Vitamin B1
Lead sponsor: University of Aarhus
Sponsor class: OTHER
First posted: 2018-08-16
Enrollment: 40
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Intervention model description: RCT and crossover
Primary purpose: TREATMENT

Brief summary: Patients with Inflammatory Bowel Disease (IBD), disease in remission and chronic fatigue will receive oral Thiamine treatment for 4 weeks in a RCT, cross-over study.

Detailed description: Patients with Inflammatory Bowel Disease (IBD), disease in remission and chronic fatigue will receive high dose oral Thiamine treatment for 4 weeks in a RCT, cross-over study.

After the high dose treatment period, participants will be randomized to 3 months treatment with Thiamine 300mg/day or placebo.

Eligibility criteria: Inclusion Criteria:

* Inflammatory Bowel Disease
* Disease in remission
* Chronic fatigue

Exclusion Criteria:

* Co-morbidity that can explain fatigue
* Pregnancy
* Non-compliance to the study procedures
* Possible surgery in the study period

Primary outcomes:
measure: Fatigue
timeFrame: After 4 weeks active treatment
Secondary outcomes:
measure: Fatigue
timeFrame: Week 8, 12, 24, and 52
measure: Health-Related Quality of Life
timeFrame: Week 4, 8, 12, 24, and 52
measure: Disease specific Health-Related Quality of Life
timeFrame: Week 4, 8, 12, 24, and 52
Other outcomes:
Locations:
city: Aarhus
country: Denmark
facility: Aarhus University Hospital
state: Central Region
Study officials:
References:
citation: Bager P, Hvas CL, Rud CL, Dahlerup JF. Long-term maintenance treatment with 300 mg thiamine for fatigue in patients with inflammatory bowel disease: results from an open-label extension of the TARIF study. Scand J Gastroenterol. 2022 Jan;57(1):37-43. doi: 10.1080/00365521.2021.1983640. Epub 2021 Sep 30.
citation: Bager P, Hvas CL, Rud CL, Dahlerup JF. Randomised clinical trial: high-dose oral thiamine versus placebo for chronic fatigue in patients with quiescent inflammatory bowel disease. Aliment Pharmacol Ther. 2021 Jan;53(1):79-86. doi: 10.1111/apt.16166. Epub 2020 Nov 18.
Clinical trial NCT02099435: Study of Hemospray for Lower Gastrointestinal Hemorrhage
Official title: A Prospective Observational Cohort Study of Hemospray for Lower Gastrointestinal Hemorrhage (APPROACH LGI)
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Colonic Diverticula
Angiodysplasia
Colonic Polyp
Keywords: Gastriointestinal
Lower gastriointestinal
Digestive
Hemostasis
Recurrent bleeding
Hemospray
Lead sponsor: Cook Group Incorporated
Sponsor class: INDUSTRY
First posted: 2014-03-28
Enrollment: 50
Sex: ALL
Minimum age (years): 19
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: clinical sites

Brief summary: This study is to evaluate the performance of Hemospray for the teatment of nonvariceal lower gastrointestinal bleeding.


Eligibility criteria: Inclusion Criteria:

* Patient in which Hemospray is used to treat an endoscopically confirmed nonvariceal lower GI bleed requiring hemostasis

Exclusion Criteria:

* Less than 19 years old
* Unwilling or unable to sign and date the informed consent
* Pregnant, lactating or planning to become pregnant within 30 days of the procedure
* Contraindicated to undergo colonoscopy

Medical/Endoscopic Exclusion Criteria

* Actual or suspected lower GI perforation or fistula
* Bleeding originating from inflammatory bowel disease (e.g., Crohn's disease or ulcerative colitis)
* Actual or suspected ischemic colitis or infectious colitis
* Unable to visualize site of active bleeding (such as suspected diverticular bleed where source is unable to be identified)
* Unable to treat active site of bleeding (e.g., bleeding site cannot be reached by the colonoscope)

Primary outcomes:
measure: Percentage of device related adverse events
timeFrame: 30 days
Secondary outcomes:
measure: Percentage of recurrent bleeding that occurs outside the blood vessel
timeFrame: 30 days
measure: Percentage of hemostasis of lower GI bleeds originating from multiple sources
timeFrame: 30 days
measure: All cause mortality
timeFrame: 30 days
Other outcomes:
Locations:
city: Edmonton
country: Canada
facility: Royal Alexandra Hospital
state: Alberta
city: Edmonton
country: Canada
facility: University of Alberta Hospital
state: Alberta
city: Kingston
country: Canada
facility: Hotel Dieu Hospital
state: Ontario
city: Montreal
country: Canada
facility: Montreal General Hospital - McGill University
state: Quebec
Study officials:
References:
citation: Hookey L, Barkun A, Sultanian R, Bailey R. Successful hemostasis of active lower GI bleeding using a hemostatic powder as monotherapy, combination therapy, or rescue therapy. Gastrointest Endosc. 2019 Apr;89(4):865-871. doi: 10.1016/j.gie.2018.10.029. Epub 2018 Oct 26.
Clinical trial NCT02077335: Study of High-dose Rate (HDR) Monotherapy for Low and Intermediate Risk Prostate Cancer
Official title: Phase II Study of High-dose Rate (HDR) Monotherapy for the Treatment of Low and Intermediate Risk Prostate Cancer
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: PHASE2
Conditions: Prostate Cancer
Keywords: Brachytherapy
Monotherapy
HDR
Lead sponsor: CSSS de Gatineau
Sponsor class: OTHER
First posted: 2014-03-04
Enrollment: 50
Sex: MALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine the clinical efficacy and toxicity of High-dose rate (HDR) brachytherapy as monotherapy for the treatment of low risk and intermediate risk prostate cancer.


Eligibility criteria: Inclusion Criteria:

* Biopsy proven Adenocarcinoma of the Prostate
* Clinical stage T1c, T2a or T2b
* PSA less than 20 ng/ml
* Gleason Score 6 or 7

Exclusion Criteria:

* Age less than 18 years
* Clinical stage T2c, T3 ou T4
* Clinical Stage N1
* Clinical Stage M1
* Prostate Specific Antigen (PSA) more than 20 ng/ml
* Gleason score 8 or higher
* IPSS score 19 or higher with alpha-blockers
* Past radiation therapy to the pelvis
* History of Collagen Vascular Disease
* History of Inflammatory Bowel Disease
* Bilateral Hip Prosthesis

Primary outcomes:
measure: Disease-free survival
timeFrame: 5 years
Secondary outcomes:
measure: Genito-urinary (GU) toxicity
timeFrame: 6 weeks, 2 years and 5 years post treatment
Other outcomes:
measure: Overall survival
timeFrame: 5 years
measure: Gastro-Intestinal (GI) Toxicity
timeFrame: 6 weeks, 2 years and 5 years post treatment
Locations:
city: Gatineau
country: Canada
facility: CSSS de Gatineau
state: Quebec
Study officials:
References:
Clinical trial NCT05783635: Alcohol Screening and Preoperative Intervention Research Study - 2
Official title: Reducing Alcohol Use Among Elective Surgical Patients Using Adaptive Interventions
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Alcohol Drinking
Keywords: Surgery
Lead sponsor: University of Michigan
Sponsor class: OTHER
Collaborators: name: National Institute on Alcohol Abuse and Alcoholism (NIAAA)
First posted: 2023-03-24
Enrollment: 440
Sex: ALL
Minimum age (years): 21
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: SEQUENTIAL
Intervention model description: The proposed study will achieve this using a Sequential Multiple Assignment Randomized Trial (SMART) design.
Primary purpose: TREATMENT

Brief summary: This sequential, multiple assignment, randomized trial will test treatments designed to reduce alcohol use before and after surgery to promote surgical health and long-term wellness.


Eligibility criteria: Inclusion Criteria:

1. Completed consent form, baseline survey, and enrollment phone call
2. Willingness to comply with all study procedures and availability for the duration of the study
3. Scheduled for select major elective surgery (non-cancer) in the next 5-12 weeks
4. Score ≥ 5 on the Alcohol Use Disorders Identification Test-Concise (AUDIT-C) based on research linking this score with increased risk of surgical complications
5. Access to a smart device or computer access with internet or wi-fi connection throughout the study period

Exclusion Criteria:

1. Exclude participants enrolled in another research study focused on alcohol use
2. History of severe alcohol withdrawal
3. Unable to speak, understand, or read English

Primary outcomes:
measure: Alcohol consumption as measured by the timeline follow-back
timeFrame: 10 months after surgical discharge
Secondary outcomes:
measure: World Health Organization Drinking (WHO) Risk Level
timeFrame: 10 months after surgical discharge
measure: Alcohol Use Disorder Identification test (AUDIT)
timeFrame: Up to 10 months after surgical discharge
Other outcomes:
Locations:
city: Ann Arbor
country: United States
facility: University of Michigan
state: Michigan
Study officials:
affiliation: University of Michigan
name: Anne Fernandez
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06893835: Comparative Study of Clinical Outcomes and Safety Between Colistin and Tigecycline
Official title: Comparative Study of Clinical Outcomes and Safety Between Colistin and Tigecycline for Multi-Drug Resistant Gram Negative Bacteria
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: PHASE4
Conditions: Infection in ICU
Keywords: colistin
Tigecycline
renal impairment
Lead sponsor: Beni-Suef University
Sponsor class: OTHER
First posted: 2025-03-25
Enrollment: 132
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Group I: 66 patients received intravenous colistin 300 mg colistin base activity (CBA) as loading dose, followed by 2.5-5mg/kg/day of CBA in 2 divided doses as a maintenance dose in intensive care unit to treat their MDR infection.

Group II: 66 patients received intravenous tigecycline100 mg single dose as loading dose, followed by 25-50 mg every 12 hours maintenance dose in intensive care unit to treat their MDR infection.
Primary purpose: TREATMENT

Brief summary: Objective from this study to compare the clinical outcomes and safety between colistin and tigecycline for multi-drug resistant gram negative bacteria.

Detailed description: Study will be in Beni-Suef university hospital. Group I: 66 patients received intravenous colistin 300 mg colistin base activity (CBA) as loading dose, followed by 2.5-5mg/kg/day of CBA in 2 divided doses as a maintenance dose in intensive care unit to treat their MDR infection and group 2 contains 66 patients received intravenous tigecycline100 mg single dose as loading dose, followed by 25-50 mg every 12 hours maintenance dose in intensive care unit to treat their MDR infection

Eligibility criteria: Inclusion criteria:

Study will include

* adult patient (male, female)
* age from 18 to 70 years
* Patients admitted to intensive care unit in study period (six months) who received intravenous colistin or tigecycline as antimicrobial drug for treatment their MDR gram negative infection.

Exclusion criteria:

* Patient admitted to intensive care unit younger than 18 years or older than 70 years.
* Liver transplantation patients.
* Patients are chronic kidney disease (CKD on hemodialysis or baseline creatinine clearance (crcl) \< 10 ml/min (estimated by Cockcroft Gault equation).
* Patients received renal replacement therapy before or during admission.
* Patient is on any other nephrotoxic drug (vancomycin, aminoglycosides, NSAIDs, cyclosporine, amphotericin B, etc.).
* Pregnant and lactating women.
* Patients refused the consent of the study.

Primary outcomes:
measure: comparison clinical success between colistin and tigecycline
timeFrame: 6 months
Secondary outcomes:
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: Pharmacy
Study officials:
affiliation: Beni-Suef University
name: Shimaa N Abd elfatah, PhD
role: STUDY_CHAIR
References:
Clinical trial NCT04434235: Effects of Additional Axial Load on Cervical Motor Control
Official title: Effects of Additional Axial Load on Cervical Motor Control
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Healthy
Keywords: cervical spine
Lead sponsor: Balgrist University Hospital
Sponsor class: OTHER
First posted: 2020-06-16
Enrollment: 100
Sex: MALE
Minimum age (years): 18
Maximum age (years): 30
Standard ages: ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Young healthy adults

Brief summary: he objective of this study is to examine the influence of additional axial load abd body position on cervical motor control in young healthy adults.

Detailed description: Motor control of the cervical spine is impotent for responsible for maintaining balance during daily living activities and to withstand external loads. Stabilization-aspects of the cervical spine is very complex, passive (ligaments, joint capsule and the skin and active (muscles), and neurological subsystems are involved. Mostly proprioceptive testing and exercises like head and neck position sense testing and re-training have been an integral part of rehabilitation. Another method to evaluate spinal motor control is the assessment of spinal stiffness. The main objective of this study is to explore the effects of additional axial loading on motion control in healthy individuals. Does the motor control of the cervical spine in healthy subjects change with additional axial load or body position? A better understanding of spinal stiffness and neck position sense leads to novel insights into spinal cervical stabilization mechanisms.

Eligibility criteria: Inclusion Criteria:

Healthy participant's Signed informed consent after being informed

Exclusion Criteria:

Acute pain Chronic neck pain Undergone Neck surgery Neck Disability Index Score \> 15

Primary outcomes:
measure: Change of neck joint-position error between differnent weight conditions
timeFrame: 20 minutes group cervical stiffness
measure: Change of neck joint-position error between two sitting positions
timeFrame: 20 minutes group Dynamic cervical stability
measure: Change of neck range of motion between different weight conditions
timeFrame: 20 minutes group cervical stiffness
measure: Change of spinal stiffness between different sitting positions and loading conditions
timeFrame: 20 minutes group cervical stiffness
Secondary outcomes:
measure: Pain during measuring
timeFrame: 2 minutes
measure: Self-administered neck mobility
timeFrame: 4 minutes
measure: Neck Disability Index
timeFrame: 4 minutes
Other outcomes:
Locations:
city: Zürich
country: Switzerland
facility: Balgrist University Hospital
state: ZH
Study officials:
affiliation: Balgrist University Hospital
name: Jaap Swanenburg, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04091035: Prevalence and Risk Factors for Common Diseases
Official title: Prevalence and Risk Factors for Common Diseases in Sweden: A Nationwide Cohort Study
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Cardiovascular Diseases
Fracture
Cancer
Lead sponsor: Region Västerbotten
Sponsor class: OTHER_GOV
Collaborators: name: Umeå University
First posted: 2019-09-16
Enrollment: 1000000
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Se above

Brief summary: By using national databases in Sweden the aim of the present project is to:

1. Investigate if the incidence of our most common diseases, such as fracture and cardiovascular disease, has changed from 1970-2017
2. To investigate whether the risk of death for our most common diseases have changed from 1970-2017.
3. To investigate the risk of a new episode after suffering from our most common diseases from 1970-2017
4. To investigate the risk factors for our most common diseases, and whether these have changed from 1970.
5. To investigate how severe disease or death affects the health of a close relative.

Detailed description: Please see above on the summary.

Eligibility criteria: Inclusion Criteria:

* All people living in Sweden that is diagnosed with our most common diseases between 1970-2017.

Exclusion Criteria:

* None

Primary outcomes:
measure: Incidence of disease
timeFrame: 1970-2017
measure: Age at diagnosis of disease
timeFrame: 1970-2017
measure: Risk of death or disease in relative
timeFrame: 1970-2017
measure: Risk factors for disease or death
timeFrame: 1970-2017
Secondary outcomes:
measure: Risk for readmission
timeFrame: 1970-2017
Other outcomes:
Locations:
Study officials:
affiliation: Umea University
name: Peter Nordström, Professor
role: STUDY_DIRECTOR
References:
Clinical trial NCT04869735: Impact of Information About Booster Vaccination Against DTPolio at 25 Years on This Booster Vaccination's Realization
Official title: Impact of Information About Booster Vaccination Against DTPolio at 25 Years on This Booster Vaccination's Realization
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Vaccination
Keywords: Booster vaccination
Adult
Information
DTPolio
Lead sponsor: Université de Reims Champagne-Ardenne
Sponsor class: OTHER
First posted: 2021-05-03
Enrollment: 2125
Sex: ALL
Minimum age (years): 25
Maximum age (years): 25
Standard ages: ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: People aged 25

Brief summary: The aim of vaccination is to protect the patient against disease by stimulating his immune system. DTPolio is a tetravalent vaccine providing protection against pertussis, diphtheria, tetanus and polio.

In France, the vaccination schedule sets the vaccination recommendations applicable to people according to their age. In this schedule, a booster of DTPolio at the age of 25 is recommended.

The vaccination coverage for patients over 16 years of age is insufficient in France.

Detailed description: The aim of the study is to evaluate impact of information about booster vaccination against DTPolio at 25 years on this booster vaccination's realization.

Eligibility criteria: Inclusion Criteria:

* aged 25 years old in 2020
* without delivery of DTPolio vaccine in 2019 or 2020

Exclusion Criteria:

* None

Primary outcomes:
measure: DTPolio vaccine delivery
timeFrame: 12 months
Secondary outcomes:
Other outcomes:
Locations:
city: Reims
country: France
facility: Université de Reims Champagne-Ardenne
Study officials:
affiliation: Université de Reims CHampahne-Ardenne
name: Brigitte VUILLEMIN
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00746135: TRI-V Heart Failure (HF) Implanted Cardioverter Defibrillator (ICD) Study
Official title: TRI-V Resynchronization in Paced Heart Failure Patients With ICD Indication.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Heart Failure
Keywords: Heart failure (NYHA class III and IV)
Ventricular Dyssynchrony
Lead sponsor: Abbott Medical Devices
Sponsor class: INDUSTRY
First posted: 2008-09-03
Enrollment: 40
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: It's the aim of this study to investigate the impact of Right Ventricular (RV) lead position (RV-apex, His bundle area, RV-apex+His bundle area) in combination with individually optimized Left Ventricular (LV) lead placement and CRT timing on the outcome of cardiac resynchronization therapy (CRT).


Eligibility criteria: Inclusion Criteria:

* Patient with indication for CRT-D: NYHA III-IV congestive heart failure, in spite of optimal medical treatment for their congestive heart failure
* LVEDD \> 55 mm or \> 30 mm/m² BSA
* EF \< 35%
* Sinus rhythm and one of the following criteria:
* QRS \>= 120 ms and PQ \>= 200ms
* or
* 2nd / 3rd degree AV block
* Written informed consent

Exclusion Criteria:

* pacemaker indication (without ICD indication)
* tricuspidal valve and/or aortic valve replacement
* Indication for revascularization.
* less than 3 month after heart surgery or myocardial infarction
* hypertrophic obstructive cardiomyopathy
* intravenous catecholamine treatment
* uncorrected thyroid function
* severe kidney disorder (creatinin \>2,5mg%)
* no written patient consent
* insufficient patient compliance
* participating in another study
* life expectancy \< 1 year due to other severe disease
* age \< 18 years
* no contraception (young women) or pregnancy

Primary outcomes:
measure: Improvement according to Packer's "Heart Failure Clinical Composite Respond"
timeFrame: 12 months post implant
Secondary outcomes:
measure: Intraoperative Increase in Left Ventricular dp/dt
timeFrame: At Implant
measure: Cardiopulmonary Capacity(Spiroergometry)
timeFrame: 12 months
measure: Change in B-type natriuretic Peptide (BNP)-Concentration
timeFrame: 12 months
measure: 6 min walk test
timeFrame: 12 months
measure: QoL assessment("Minnesota Living with Heart Failure = MLHF)
timeFrame: 12 months
measure: 12 channel ECG
timeFrame: 12 months
measure: 2D-echo optimized EF
timeFrame: 12 months
measure: Complications and morbidity
timeFrame: 12 months
Other outcomes:
Locations:
city: Bad Rothenfelde
country: Germany
facility: Departement of Cardiology - Electrophysiology- Heart Centre Osnabrück - Bad Rothenfelde
Study officials:
affiliation: Departement of Cardiology - Electrophysiology- Heart Centre Osnabrück - Bad Rothenfelde
name: Wolfgang Kranig, MD
role: PRINCIPAL_INVESTIGATOR
References: